Top 50 Biotechnology VC Funds & Investors in Oceania (October 2023)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Uniseed Ventures
VC Fund
|
21 | Australia, United States, United Kingdom | Series A, Seed | Biotechnology, Manufacturing, Health Care | $364k–$6.4M |
|
Brandon Capital Partners
VC Fund
|
15 | Australia, United States, United Kingdom | Series A, Seed, Series B | Biotechnology, Health Care, Medical | $642k–$25M |
|
Medical Research Commercialisation Fund (MRCF)
VC Fund
|
11 | Australia, United States, United Kingdom | Series A, Seed, Series B | Biotechnology, Health Care, Medical | $1.3M–$13M |
|
Stoic VC
VC Fund
|
7 | Australia, United States, United Kingdom | Seed, Series A | Biotechnology, Medical, Health Care | |
|
Icehouse Ventures
VC Fund
|
7 | New Zealand, United States, Australia | Seed, Series A | Software, SaaS, Information Technology | $450k–$21M |
|
OneVentures
VC Fund
|
6 | Australia, United States, Israel | Series A, Debt Financing | Software, Health Care, Information Technology | $1.5M–$20M |
|
Artesian VC
VC Fund
|
5 | Australia, United States, Hong Kong | Seed, Series A, Pre-Seed | Software, Artificial Intelligence, Information Technology | $70k–$12M |
|
Melbourne Angels
VC Fund
|
5 | Australia, United States, New Zealand | Angel, Seed | Biotechnology, Information Technology, Manufacturing | $32k–$893k |
|
New Zealand Venture Investment Fund
VC Fund
|
5 | New Zealand, United States, Japan | Seed, Series A, Angel | Software, Biotechnology, SaaS | $400k–$8.5M |
|
Enterprise Angels
VC Fund
|
5 | New Zealand, United States, United Kingdom | Seed, Angel | Software, Information Technology, Health Care | $149k–$2.4M |
|
Main Sequence Ventures
VC Fund
|
4 | Australia, United States, Philippines | Series A, Seed, Series B | Software, Artificial Intelligence, Information Technology | $1.3M–$49M |
|
K1W1
VC Fund
|
4 | New Zealand, United States | Seed, Series A | Software, Biotechnology, SaaS | |
|
Clean Energy Finance Corporation
VC Fund
|
3 | Australia, United States | Series B, Series A, Seed | Energy, Solar, Renewable Energy | $2.5M–$19M |
|
Finistere Ventures
VC Fund
|
3 | United States, Israel, New Zealand | Series B, Series C, Series A | Agriculture, Biotechnology, Farming | $1.1M–$200M |
|
Yuuwa Capital
VC Fund
|
3 | Australia | Series A, Seed, Series B | Biotechnology, Analytics, Health Care | $128k–$6.1M |
|
Starfish Ventures
VC Fund
|
3 | United States, Australia, Philippines | Series A, Series B | Software, Enterprise Software, Information Technology | $642k–$14M |
|
Matū Fund
VC Fund
|
3 | New Zealand, United States | Seed | Biotechnology, Robotics, Nanotechnology | |
|
Horizons Ventures
VC Fund
|
3 | United States, United Kingdom, Canada | Series A, Series B, Seed | Biotechnology, Artificial Intelligence, Software | $750k–$70M |
|
BridgeLane Capital
VC Fund
|
2 | Australia, Germany | Seed, Series B | Software, Financial Services, Health Care | $642k–$13M |
|
IP Group
VC Fund
|
2 | United Kingdom, United States, Australia | Seed, Series A, Series B | Health Care, Biotechnology, Therapeutics | $369k–$61M |
|
Global Health Investment Fund (GHIF)
VC Fund
|
2 | United States, India, Austria | Series B, Series C | Health Care, Biotechnology, Medical Device | $4.5M–$17M |
|
Folklore Ventures
VC Fund
|
2 | Australia, New Zealand, United States | Seed, Series A | Software, Apps, Information Technology | $250k–$15M |
|
Grok Ventures
VC Fund
|
2 | Australia, United States, Hong Kong | Series A, Series B, Seed | Renewable Energy, Software, Internet of Things | $1M–$465M |
|
Sydney Angels
VC Fund
|
2 | Australia, United States | Seed, Angel | Software, SaaS, Apps | $161k–$895k |
|
South Australian Venture Capital Fund
VC Fund
|
2 | Australia | Series A, Series B | Health Care, Biotechnology, SaaS | |
|
Vectr
VC Fund
|
2 | United States, Hong Kong, Singapore | Seed, Series A, Pre-Seed | FinTech, Artificial Intelligence, Financial Services | $425k–$35M |
|
Lowercarbon Capital
VC Fund
|
2 | United States, United Kingdom, France | Seed, Series A | Biotechnology, Renewable Energy, Energy | $2.7M–$50M |
|
Possible Ventures
VC Fund
|
2 | Germany, Australia, United States | Seed, Pre-Seed, Series A | Software, Information Technology, Biotechnology | $350k–$43M |
|
Rabobank Food & Agri Innovation Fund
VC Fund
|
2 | United States, The Netherlands, Canada | Series A, Series B, Seed | Agriculture, AgTech, Farming | $3.8M–$15M |
|
Brisbane Angels
VC Fund
|
2 | Australia, United States, New Zealand | Seed, Angel | Software, Information Technology, Artificial Intelligence | $321k–$835k |
|
Plymouth Growth
VC Fund
|
1 | United States, Canada, Australia | Series A, Series B | Software, Information Technology, Enterprise Software | $500k–$7.8M |
|
ATP Innovations
VC Fund
|
1 | Australia | Health Care, Biotechnology, Pharmaceutical | ||
|
Movac
VC Fund
|
1 | New Zealand, United States, Australia | Seed, Series A | Software, E-Commerce, SaaS | $774k–$16M |
|
Understorey Ventures
VC Fund
|
1 | United States | Series A | Software, Data and Analytics, Information Technology | |
|
NOAB Ventures
VC Fund
|
1 | Australia, New Zealand | Pre-Seed | Solar, Energy, Energy Storage | |
|
Powerhouse Ventures
VC Fund
|
1 | United States, New Zealand, The Netherlands | Seed, Series A | Solar, FinTech, Big Data | $500k–$7M |
|
Outset Ventures
VC Fund
|
1 | New Zealand | Seed, Pre-Seed | CleanTech, Biotechnology, Product Research | |
|
Lilly Ventures
VC Fund
|
1 | United States, Israel, Australia | Series C, Series B, Series A | Biotechnology, Health Care, Therapeutics | $4M–$44M |
|
Bioplatforms Australia
VC Fund
|
1 | Australia | Pre-Seed | AgTech, Farming, Agriculture | |
|
Southern Cross Venture Partners
VC Fund
|
1 | United States, Australia, Singapore | Series B, Series A | Software, Manufacturing, Renewable Energy | $2M–$15M |
|
Grand Challenges Canada
VC Fund
|
1 | Canada, United States, Australia | Grant, Seed, Debt Financing | Health Care, Medical Device, Biotechnology | $100k–$3.3M |
|
Custos Privatstiftung
VC Fund
|
1 | Israel, Austria, New Zealand | Series B, Seed, Series C | Software, Biopharma, Nutrition | |
|
Thistledown Capital
VC Fund
|
1 | Canada, Germany, Australia | Series A | Energy, Laser, Electronics | |
|
Empath Ventures
VC Fund
|
1 | Australia | Seed, Convertible Note | Biotechnology | |
|
Even Capital
VC Fund
|
1 | New Zealand | Seed, Series C | FinTech, Biotechnology, Product Research | |
|
Twynam Agricultural Group
VC Fund
|
1 | United States, Australia, Singapore | Series A, Seed | Agriculture, Food Processing, Seafood | $1.9M–$33M |
|
UniSA Ventures
VC Fund
|
1 | Australia | Seed | Software, Health Care, Biotechnology | |
|
Investible
VC Fund
|
1 | Australia, United States, Singapore | Seed, Series A, Pre-Seed | Software, E-Commerce, Information Technology | $125k–$6.1M |
|
Playford Capital
VC Fund
|
1 | Australia | Series A, Series B | Health Care, Biotechnology, Medical Device | |
|
HealthCare Ventures
VC Fund
|
1 | United States, Australia, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Pharmaceutical | $4.4M–$50M |
| Access all 50 VC funds in Oceania Biotechnology startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.
Show more...Investment focus
- Industry: Biotechnology, Manufacturing, Health Care
- Stage:Series A, Seed
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 56
- Round size: Seed $364k–$2M; Series A $1.3M–$6.4M
- Lead/follow: 13% lead, 87% follow
- Last fund: May invest from a new fund soon — raised $13M in 2017
Portfolio highlights
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
- Morse Micro — Smarter, farther, better. Meet the latest Wi-Fi, HaLow, 802.11ah. 10X FARTHER>1Km range, 100x area, 1000x volume 10X EFFICIENCYMulti-year on a single
- Tiny Bright Things — Melbourne-based company Tiny Bright Things was cofounded in 2020 by long-time research collaborators Ray Dagastine and Chris Bolton. We invented Halo microscopy to transform the way researchers and manufacturers look at small or transparent things. This helps manufacturers in areas like agrichemicals and pharmaceuticals (where the size and shape ofpowders are critical) and researchers at every stage of discovery— particularly in nanotechnology (where samples are especially tiny) and life sciences (where samples are often also transparent).
Brandon Capital invests in the most promising biomedical opportunities that have the potential to improve the lives of patients.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Series B
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 39
- Round size: Seed $642k–$6.4M; Series A $4M–$20M; Series B $5M–$25M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $210M in 2019
Portfolio highlights
- CatalYm — Catalym develops antibodies against a placental factor which is overexpressed by various tumour types.
- Entact Bio — Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed tocreate enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins.
- NRG Therapeutics — energizing drug discovery in neurodegenerative diseases.
Medical Research Commercialisation Fund (MRCF) provides dedicated, investment funding to support the commercialisation of early-stage medical research discoveries that originate from its member institutes. The collaborative nature of the MRCF seeks to foster best practice in the commercialisation of medical innovations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Series B
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 25
- Round size: Series A $1.3M–$13M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Glyscend — Glyscend develops a revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway. Thecompany's technology is an orally ingestible intestinal coating that prevents the stimulation of duodenal mucosa and inhibits key neurohormonal pathways in the proximal gut. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. Meanwhile, the company aims to provide endocrinologists and primary care physicians with the innovative tools they need to treat the disease instead of merely managing it. It was founded in 2014 by co-founders Ashish Nimgaonkar, Michael Parlato, and Pratik Patel.
- Currus Biologics — Currus Biologics is a biotechnology company that develop CAR-T cell therapies for the treatment of solid tumour cancers.
- Azura Ophthalmics — Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatmentoptions are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S.
Stoic VC is an early-stage venture fund backing founders at the forefront of University Innovation. We partner with Uniseed to accelerate the commercialisation of university research across the ANZ.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Seed, Series A
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 20
- Lead/follow: 5% lead, 95% follow
Portfolio highlights
- Ena Respiratory — Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines.Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterialdissemination to the lungs.
- BioScout — Welcome to BioScout, your partner in revolutionizing the agriculture industry with cutting-edge automated disease detection technology for crop growers and viticulture. Our high-level introduction and detailed insights into our innovative solutions, exceptional collaborations, and dedicated team make it easy to understand WHO we are, WHAT we do, and HOW we do it. Stay updated with valuable resources, customer portal, and regular content via our blog. Contact us today to collaborate and optimize your farm's productivity and sustainability.
- Lenexa Medical — Lenexa Medical is driving towards better healthcare solutions for patients in hospital and aged-care by preventing pressure injuries and empowering clinicans.
Icehouse Ventures is an early-stage venture capital firm. We exist to back the world's bravest Kiwi founders, launching global companies from New Zealand.
Show more...Investment focus
- Industry: Software, SaaS, Information Technology
- Stage:Seed, Series A
- Geography: New Zealand, United States, Australia
Investor stats
- Total investments: 125
- Round size: Seed $450k–$2.6M; Series A $1.4M–$21M
- Lead/follow: 10% lead, 90% follow
- Last fund: Likely still investing — fund raised in 2021
Portfolio highlights
- DataMasque — Simply mask your sensitive data while maintaining its function for testing, development, training and analytics. DataMasque makes it safe to explore, implement and harness the opportunities that data provides, free from privacy concerns or compromise.
- Aquila — We're powering the future by building and operating an infinitely scalable energy network.
- Scentian Bio — Scentian Bio operates as a platform that provides ultimate sensing solution.
OneVentures is one of Australia’s leading venture capital firms, with over $330M in funds under management. But they do more than invest. They take companies to that all important next stage, by actively shaping their future. They apply their years of international experience, operational and executional expertise to accelerate the growth of theirportfolio companies. A global growth focus drives their investment selection with their current portfolio including companies with truly innovative products tackling multi-billion-dollar problems, from needle-free vaccinations to virtual communications to adaptive e-learning.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Series A, Debt Financing
- Geography: Australia, United States, Israel
Investor stats
- Total investments: 64
- Round size: Series A $1.5M–$20M; Debt Financing $1.8M–$4M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely still investing — raised $128M in 2022
Portfolio highlights
- Vaxxas — Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia.
- BiVACOR — BiVACOR is a privately held company founded in 2008. Their staff includes world-class engineers, medical specialists, and business executives, who are diligently working to advance this ground-breaking technology. Together, they have established a strong collaborative network that extends both nationally and internationally. Their worldheadquarters is located in Houston, Texas, USA, and their international office is in Brisbane, Australia.
- ImmVirX — ImmVirX is an Australian company founded in 2019 with a mission to improve outcomes for patients with cancer types in which immunotherapy treatments have limited effect.
Artesian Capital Management is an alternative investments management company, which was spun out of ANZ Banking Group's capital markets business in 2004, with backing from ANZ Private Equity. Artesian's founding partners, purchased ANZ's stake in 2005. The company has subsequently been fully owned by partners and staff. Since 2004,Artesian has managed specialised funds focused on credit arbitrage and relative-value strategies across global financial markets. In 2008, while continuing to manage credit relative value investment strategies from its New York, London and Singapore offices, Artesian began to make principal investments in seed/early-stage ventures from its offices in Sydney, Melbourne and Shanghai. In 2011, Artesian launched the first of its early stage venture capital funds and now manages AUD +255m. Artesian's VC strategy is to partner with best of breed accelerators, incubators, angel groups and university programs. In 2017, Artesian launched its China VC Fund with a USD 50m cornerstone investment industry super fund Hostplus. Artesian will soon launch a Southeast Asia VC Fund.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Series A, Pre-Seed
- Geography: Australia, United States, Hong Kong
Investor stats
- Total investments: 172
- Round size: Seed $96k–$2.4M; Pre-Seed $70k–$1.5M; Series A $3.3M–$12M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — fund raised in 2021
Portfolio highlights
- ZoomAgri — ZOOMAGRI provides an assessment of agricultural commodities to all participants of Agri supply chain via AI, computer vision and IoT.
- Supplynote — End-to-end supply chain management tool to track inventory, orders, payments and suppliers online
- Navi Medical Technologies — Navi Medical Technologies is a medical device development company.
Melbourne Angels was formed in Melbourne, Australia in early 2007. Melbourne Angels is the leading group of private investors in Victoria who actively invest in early stage and growth technology companies.The group has a strong and experienced core of members that generate deal flow, are experienced in evaluation of business propositions and actas mentors for the other members and the entrepreneurs. The members vary in age, gender, ethnicity, profession and type of experience. All members have experience of success at being entrepreneurial.This award winning group is consistently one of the most active startup investors in the country.
Show more...Investment focus
- Industry: Biotechnology, Information Technology, Manufacturing
- Stage:Angel, Seed
- Geography: Australia, United States, New Zealand
Investor stats
- Total investments: 34
- Round size: Seed $32k–$771k; Angel $601k–$893k
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- Tayble — Spend more time enjoying your food and less time waiting.We hate waiting...For anything...And food and drinks are no exception!If your hobbies include:- Waiting in line - Calling out to a waiter - Watching the kettle boil - Calculating your split of the billPLEASE DO NOT DOWNLOAD THIS APP... YOU'LL HATE IT!But if you're likeus...And want your food and drinks ready exactly when you are...Or to leave a restaurant without worrying about your bill...Then step right up, this bad boy's for you!With Tayble, you’ll never have to flag down a waiter... EVER!Simply order from your "Tayble"Or before you even arrive...Leave the rest to us and the 1,000's of minions in the cloud that keep this all running!You’ll be left asking where has this been all my life, guaranteed!*(Definitely not a real guarantee)
- Insite AI — We create predictability for consumer brands in the unpredictable world of retail. Game-changing technology that attacks consumer brands' hardest problems.
- Apop Imaging — Apop Imaging develops and commercialises novel imaging, diagnostic and therapeutic tools to improve patient outcomes based on our proprietary calcitonin receptor antibody technology.
Your guide to finding and using government services.
Show more...Investment focus
- Industry: Software, Biotechnology, SaaS
- Stage:Seed, Series A, Angel
- Geography: New Zealand, United States, Japan
Investor stats
- Total investments: 35
- Round size: Seed $417k–$1.2M; Angel $400k–$417k; Series A $1.4M–$8.5M
- Lead/follow: 6% lead, 94% follow
Portfolio highlights
- Insite AI — We create predictability for consumer brands in the unpredictable world of retail. Game-changing technology that attacks consumer brands' hardest problems.
- Invert Robotics — Invert Robotics develops robotic NDT inspection technologies for the maintenance of industrial equipment in the food and beverage, pharmaceutical, and oil and gas industries. Invert Robotics highly skilled team of engineers have developed a world leading modular inspection platform suitable for use across a range of industries and applications.
- Surgical Design Studios — The Insides Company is the leading provider of chyme reinfusion solutions for intestinal failure
Connecting startup business owners with angel investors to raise capital . Access a network of expertise and investment opportunities.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Angel
- Geography: New Zealand, United States, United Kingdom
Investor stats
- Total investments: 98
- Round size: Seed $149k–$2.4M; Angel $223k–$655k
- Lead/follow: 7% lead, 93% follow
- Last fund: May invest from a new fund soon — raised $12M in 2019
Portfolio highlights
- Cropsy Technologies — Cropsy's mission is to deliver disruptive, scalable technology to every fruit grower to unlock the full potential of their land with insights that were impossible before. Our proprietary AI-enabled hardware allows growers to monitor every plant, understand the whole crop, and track how it changes over time. These insights help growers optimiseall their decision making. The system is a simple tractor add-on, so growers do all their daily operations while Cropsy looks out for problems. Cropsy is poised to set the new gold standard for growing, with recommendations, forecasts, and providing certainty to every grower, every season.
- Cetogenix — Cetogenix is a clean technology business dedicated to creating long-term solutions to global climate change.
- Zenno Astronautics — At Zenno Astronautics, our hardware and software products ensure satellite missions are effectively managed, guaranteeing maximum economic returns and responsible use of space.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!We work with inventors who are building something hard from their unique expertise in science. These inventors are building the industries that will thrive for the decades to come. We have a unique working model to accelerate a company's pathway to scale.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Series A, Seed, Series B
- Geography: Australia, United States, Philippines
Investor stats
- Total investments: 65
- Round size: Seed $1.3M–$6M; Series A $3.8M–$22M; Series B $12M–$49M
- Lead/follow: 54% lead, 46% follow
- Last fund: May invest from a new fund soon — raised $161M in 2021
Portfolio highlights
- Endua — Endua is building the next generation of clean energy deep storage to power communities, remote industries and off-grid infrastructure at the flick of a switch - all day and night
- Jdoodle — JDoodle is an Online Compiler, Editor, IDE for Java, C, C++, PHP, Perl, Python, Ruby and many more. You can run your programs on the fly online, and you can save and share them with others. Quick and Easy way to compile and run programs online.
- Number 8 bio — Number 8 bio objective is to decarbonize agriculture while feeding the world's rising population. This can be accomplished by harnessing the power of trillions of carbon-hungry bacteria that feed on harmful greenhouse gases and turn them into profitable animal feeds.
K1W1 provides startups and businesses in New Zealand with early and later-stage venture investments.
Show more...Investment focus
- Industry: Software, Biotechnology, SaaS
- Stage:Seed, Series A
- Geography: New Zealand, United States
Investor stats
- Total investments: 61
- Lead/follow: no public data
Portfolio highlights
- Daisy Lab — Daisy Lab pioneers precision fermentation technology in New Zealand
- Aquafortus — Aquafortus specializes in providing enviornmental services and commercializes proprietary zero liquid discharge technology.
- Mint Innovation — Founded in 2016, members of the Mint Innovation team have a strong background in chemistry, biotechnology, and leveraging IP in the industrial sector. They are scaling their technology in their Auckland plant and labs to demonstrate the commercial application of their biometallurgy processes for metal recovery.
The Clean Energy Finance Corporation invests, applying commercial rigour, to increase the flow of finance into the clean energy sector. Their mission is to accelerate Australia's transformation towards a more competitive economy in a carbon constrained world, by acting as a catalyst to increase investment in emissions reduction. They do thisthrough an investment strategy focused on cleaner power solutions, including large and small-scale solar, wind and bioenergy; and a better built environment, with investments to drive more energy efficient property, vehicles, infrastructure and industry. The CEFC also invests with co-financiers to develop new sources of capital for the clean energy sector, including climate bonds, equity funds, aggregation facilities and other financial solutions. The CEFC operates under the Clean Energy Finance Corporation Act 2012.
Show more...Investment focus
- Industry: Energy, Solar, Renewable Energy
- Stage:Series B, Series A, Seed
- Geography: Australia, United States
Investor stats
- Total investments: 41
- Round size: Seed $6M–$16M; Series A $2.5M–$13M; Series B $5M–$19M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- Infradebt — Infradebt t is a specialist fund manager providing clients with direct access to infrastructure private debt markets.
- Gunn Agri Partners — Gunn Agri Partners is an agricultural investment company that offers advice and services for acquisitions, asset, farm, and fund management.
- HydGene Renewables — Our mission is to accelerate adoption of low carbon technology by providing an alternative green hydrogen solution.
Finistere Ventures is an agricultural technology and life sciences venture capital investor. Founded in 2005, the company partners with other entrepreneurs and creative thinkers to build innovative companies that have the potential to transform modern agriculture, increase food security, improve nutrition, and enhance sustainability. Their appliedexperience as operators, and pioneering role in Ag Tech, is actively utilized to benefit its portfolio companies and Partners. Finistere has global access to the best new technologies from centers of Ag Tech excellence in the U.S., Australia, Israel, New Zealand, and Canada through its venture partner networks. Finistere’s locations in San Diego and Palo Alto, California keeps them connected to the centers of mainstream venture investment and the world’s leading innovation ecosystem.
Show more...Investment focus
- Industry: Agriculture, Biotechnology, Farming
- Stage:Series B, Series C, Series A
- Geography: United States, Israel, New Zealand
Investor stats
- Total investments: 49
- Round size: Series A $1.1M–$9M; Series B $5.3M–$200M; Series C $3.4M–$30M
- Lead/follow: 39% lead, 61% follow
- Last fund: May invest from a new fund soon — raised $28M in 2021
Portfolio highlights
- Scentian Bio — Scentian Bio operates as a platform that provides ultimate sensing solution.
- Animol Discovery — Animol is building its own pipeline of break-through proprietary veterinary small molecules led by a team of animal health industry experts with vast experience in bringing drugs to market. With our unique and powerful technology platform we deliver innovative medicines that are specifically designed for the needs of veterinary patients.
- Growers Edge — Growers Edge leverages data science to build grower-relevant risk management solutions to meet ever-changing agricultural demands.
Yuuwa Capital is a $40M early-stage venture capital firm based in Perth, Western Australia. They are actively seeking outstanding investment opportunities where Yuuwa can provide both capital and expertise to help founders, management and early investors to turn good ideas into great companies.
Show more...Investment focus
- Industry: Biotechnology, Analytics, Health Care
- Stage:Series A, Seed, Series B
- Geography: Australia
Investor stats
- Total investments: 16
- Round size: Seed $128k–$771k; Series A $964k–$4.2M; Series B $2.6M–$6.1M
- Lead/follow: 63% lead, 37% follow
Portfolio highlights
- Nexgen Plants Pty Limited — Healthy plants, healthy people, living planet. Nexgen develop's plants for future generations that will improve the environment and health of future generations.
- icetana — icetana Motion Intelligence dramatically improves the active monitoring of security surveillance networks, with AI video anomaly detection and video analytics.
- Agworld Pty Ltd — Agworld Farm Management software allows you to collect data at all levels and enables you to extract maximum value from this data; optimising profitability. The Agworld ecosystem is utilised by growers, agronomists and service providers on farms across the world.
Starfish Ventures is an Australian venture capital firm focused on information technology, life sciences, and clean technology companies.
Show more...Investment focus
- Industry: Software, Enterprise Software, Information Technology
- Stage:Series A, Series B
- Geography: United States, Australia, Philippines
Investor stats
- Total investments: 51
- Round size: Series A $642k–$6.6M; Series B $2.5M–$14M
- Lead/follow: 53% lead, 47% follow
- Last fund: May invest from a new fund soon — raised $119M in 2008
Portfolio highlights
- Aktana — Build stronger relationships with HCPs using Aktana's artificial intelligence (AI) platform for life sciences to optimize omnichannel engagement.
- DesignCrowd — Crowdsourced logo, freelance graphic and web design at DesignCrowd. 1,136,169 freelance designers compete to create amazing designs for your business. Start Today!
- Marani — Marani Health is developing a prenatal care platform which includes a wearable, textile-based product to measure key vital statistics of women and their developing fetus, for use during pregnancy, labor & delivery. The products utilize Artificial Intelligence to better assess health & wellness during pregnancy, labor & delivery. Maraniis collaborating with key partners including The Mayo Clinic.
Investing in scalable science and deep tech start-ups in Aotearoa NZ. We operate venture capital funds that invest in science and deep tech through a hands-on, active approach.
Show more...Investment focus
- Industry: Biotechnology, Robotics, Nanotechnology
- Stage:Seed
- Geography: New Zealand, United States
Investor stats
- Total investments: 7
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Ligar — Novel technology to rapidly and cost effectively capture and recover specific molecules or groups of molecules from liquids, such as bioactives, bitter flavours or contaminants from natural extracts, wine, water, juices, coffee and wastewater. [et_pb_column type="1_3"
- Alimetry — Alimetry is a health technology startup based in Auckland, New Zealand, developing breakthrough solutions for diagnosing disorders of gastrointestinal (GI) function.
- PowerON — Dielectric Elastomers for Soft Robotics
Investing in the deep science and technology that can propel humanity towards a radically better future.
Show more...Investment focus
- Industry: Biotechnology, Artificial Intelligence, Software
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 216
- Round size: Seed $750k–$11M; Series A $6M–$30M; Series B $8M–$70M
- Lead/follow: 45% lead, 55% follow
Portfolio highlights
- BioLoomics — BioLoomics is a preclinical stage biotechnology company that uses evolution in a microscope to develop drug discovery tools and protein drugs. Our VariVolve platform tests millions of protein designs for a targeted activity in hours, enabling efficient mining of the vast chemical space of protein designs. A strong advantage of our approach is theuse of whole intact cells as test vessels that capture complex drug behavior not attainable in conventional assays.
- Erthos — erthos is a producer of biodegradable packaging materials intended to replace traditional polystyrene and polypropylene inputs.
- ZeroAvia — ZeroAvia is producing the world's first practical zero emission aviation powertrain, initially targeting 20-seat airplanes to start replacing dirty jet fuel in regional transport
The BridgeLane Group is a privately-owned asset management firm specialising in the agricultural, real estate and innovation sectors. A significant global player in agriculture with a multi-decade record in large scale farming, the Group has a proud history in residential property development, comme
Show more...Investment focus
- Industry: Software, Financial Services, Health Care
- Stage:Seed, Series B
- Geography: Australia, Germany
Investor stats
- Total investments: 16
- Round size: Seed $642k–$2M; Series B $5M–$13M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Agerris — Agerris is a field robotics and AI start-up for the agriculture industry, based on technology created at the Australian Centre for Field Robotics, the University of Sydney, where they have been developing air and ground robotic solutions for the agriculture industry since 2005.
- Sprout Stack —
- Evrima Technologies — Our clinical trial recruitment and management services put participants first. Trusted, timely clinical trial results are a good thing - for everybody.
IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Therapeutics
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Australia
Investor stats
- Total investments: 157
- Round size: Seed $369k–$6.4M; Series A $1.8M–$17M; Series B $7.4M–$61M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — last raise in 2014
Portfolio highlights
- AccelerComm — Our patented, market-leading IP solutions for 4G and 5G are configurable for quick, high-performance implementations across a wide range of applications.
- Deep Render — Deep Render Ltd. is a spin-out from the Department of Computing at Imperial College London. We are a London based AI start-up that is developing the next generation of media compression algorithms. Our proprietary and patented technology is at the forefront of machine learning research. Furthermore, our Biological Image Compression results arestate-of-the-art, providing at least a 50% efficiency gain over the previous standards
- Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!The Global Health Investment Fund (GHIF) is a $108 million social impact investment fund designed to provide financing to advance the development of drugs, vaccines, diagnostics and other interventions against diseases that disproportionately burden low- and middle-income countries. GHIF supports late-stage innovations for public health challengessuch as malaria, pre-eclampsia, cholera, HIV and river blindness, with an emphasis on infectious diseases and maternal/infant health issues that cause significant morbidity and mortality in resource-limited settings. GHIF may also make investments that improve or expand access to existing products—such as developing pediatric formulations of approved therapeutics or improving the stability of widely-used global health vaccines.As an investment fund with a limited time-horizon, GHIF seeks opportunities that have a high probability of successful commercialization within two or three years. Products with “dual market” potential are of greatest interest; i.e., those that will have a clear impact on public health in developing countries but also have value in high-income countries. High-volume / low-margin products, such as essential vaccines, are also of significant interest.GHIF employs a range of investment structures including mezzanine debt, convertible debt, preferred equity and project financing with an average investment target of approximately $10 million per project. Each GHIF project must advance the Fund’s social impact objectives and demonstrate the ability to achieve commercial success.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series B, Series C
- Geography: United States, India, Austria
Investor stats
- Total investments: 18
- Round size: Series B $7.5M–$17M; Series C $4.5M–$14M
- Lead/follow: 39% lead, 61% follow
- Last fund: May invest from a new fund soon — last raise in 2012
Portfolio highlights
- Monod Bio — Monod Bio l Simple. Powerful. Biosensors for Medicine & Biotech.
- CXL Ophthalmics — CXLO is developing a minimally invasive treatment for an ectatic corneal disease that can bring early intervention to millions of patients globally.
- Endpoint Health — Endpoint Health is a precision-first therapeutics company. By rewriting the molecule-first drug development model, we aim to deliver precision therapies that have the potential to improve outcomes for patients with immune-driven illnesses.
Folklore is a team of investors, founders, and builders committed to supporting Australian and New Zealand tech founders. We are a first cheque to forever investment firm, and we believe in the power of founder vision and the potential of teams, right from the start.
Show more...Investment focus
- Industry: Software, Apps, Information Technology
- Stage:Seed, Series A
- Geography: Australia, New Zealand, United States
Investor stats
- Total investments: 31
- Round size: Seed $250k–$4.8M; Series A $500k–$15M
- Lead/follow: 61% lead, 39% follow
- Last fund: May invest from a new fund soon — raised $40M in 2017
Portfolio highlights
- Swoop Aero — Transforming how the world moves by making access to the skies seamless.
- HealthMatch — HealthMatch is a medical technology company that applies machine learning and artificial intelligence to clinical data to save lives.We aim to dramatically accelerate patient recruitment to clinical trials, and progress life-saving cures onto the market faster than existing practices allow.For clinicians and patients, there is a real struggleto identify and find appropriate trials, particularly where the criteria relating to each trial is inconsistently articulated. HealthMatch encodes qualifying questions relating to each patients condition. The platform matches responses to its trial dataset, and confirms only the correct-match trials for that patient — thereby streamlining the identification of suitable trials and facilitating a patient’s application to those trials.With Ai and software at the core, HealthMatch delivers a radically simple product to match patients with drug trials, backed by an execution approach to data that is deceptively complex to achieve and replicate. In doing so, HealthMatch is dramatically changing an industry that has essentially not moved beyond telephones and excel spreadsheets.
- SimConverse — SimConverse is a simulation platform that uses generative AI to play the role of any patient, colleague or casualty.
Grok Ventures is a private investment company. They back world-class teams solving big problems to shape a better future. They invest in fast growing technology-enabled businesses.
Show more...Investment focus
- Industry: Renewable Energy, Software, Internet of Things
- Stage:Series A, Series B, Seed
- Geography: Australia, United States, Hong Kong
Investor stats
- Total investments: 43
- Round size: Seed $1M–$7.1M; Series A $2.6M–$75M; Series B $100M–$465M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Lydian — Lydian aims to accelerate the decarbonization of the chemical industry by electrifying the chemical production process. Founded in 2021 by Branko Zugic, Lydian is headquartered in
- Loam Bio — Loam Bio is developing tech that allows for crops to be inoculated with symbiotic micro-organisms.
- Fleet Space Technologies — Fleet is an agile, next generation connectivity company. Our mission is to Connect Everything using cutting-edge communications and space technologies to maximise the resource efficiency of human civilisation and enable the next industrial revolution with our free, ubiquitous connectivity platform.
Sydney Angels is a not-for-profit angel investment membership organisation. Since our establishment in 2008, they have stayed true to our mission of supporting the early-stage ecosystem by running processes and events that connect our investing members with promising early-stage companiesThey believe that encouraging smart investment in startupcompanies will benefit both our members’ portfolios and Australia’s emergent innovation economy.They see this as the ultimate win-win situation. Sydney Angels is led by an elected committee of ten volunteers who meet weekly. It is supported by an operations manager and alliance partners.
Show more...Investment focus
- Industry: Software, SaaS, Apps
- Stage:Seed, Angel
- Geography: Australia, United States
Investor stats
- Total investments: 42
- Round size: Seed $161k–$895k; Angel $330k–$890k
- Lead/follow: 60% lead, 40% follow
- Last fund: May invest from a new fund soon — last raise in 2016
Portfolio highlights
- Kapiche — Instant insights. No set up or coding. The Kapiche feedback analytics platform helps you ingest and analyze mountains of customer feedback in minutes.
- Remi AI — A.I-Powered Demand Forecasting, Supply Chain AI, & Price Optimisation | Remi AI
- Trendspek — Trendspek is the drone data solution asset managers use to make empowered decisions and ensure absolute asset knowledge. Conduct complete visual inspections from any web browser. Extract detailed insights without a site visit. Use powerful tools to analyse the structure and build a complete picture of asset condition. Enhance predictive maintenanceby closely monitoring trends. View different models side by side to observe important differences. Refine your understanding of an ever-changing asset.
South Australian Venture Capital Fund - helping build dynamic and innovative South Australian startups / scaleups and accelerate their growth to a national and global scale.
Show more...Investment focus
- Industry: Health Care, Biotechnology, SaaS
- Stage:Series A, Series B
- Geography: Australia
Investor stats
- Total investments: 4
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Lumary — Simplify Your Care Management Optimise Your Organisation Create Better Wellbeing
- BiomeBank — BiomeBank is a clinical stage biotechnology company with a mission to treat our microbiome and prevent disease by restoring gut microbial ecology.
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
Vectr is a venture firm based in Hong Kong. They combine investment, creation and growth to deliver game-changing impact to teams ready to tackle global issues, transform industries and improve the lives of millions.That combines capital, creation and partnership to deliver game-changing impact. We strive to be the ideal partner for founders thatare building transformation products and looking to expand their businesses into asia.
Show more...Investment focus
- Industry: FinTech, Artificial Intelligence, Financial Services
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Hong Kong, Singapore
Investor stats
- Total investments: 72
- Round size: Seed $425k–$4M; Series A $1M–$35M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Percent — Unlock private credit investments with Percent. Access alternative investments on the platform powering the future of private markets.
- Micro Connect — Micro Connect provides market infrastructure, fintech, and platform development.
- MasterExchange — Trading platform for music rights leveraging emerging technology to create friction free and compliant investment opportunities to everyone.
Lowercarbon Capital backs kickass companies slashing CO2 emissions, sucking carbon out of the sky, and buying us time to unf**k the planet.
Show more...Investment focus
- Industry: Biotechnology, Renewable Energy, Energy
- Stage:Seed, Series A
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 102
- Round size: Seed $2.7M–$11M; Series A $6.5M–$50M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Dioxycle — Dioxycle is develop electrolyser solutions for carbon dioxide emissions.
- Isometric — Isometric is a carbon removal registry and science platform
- Arc Boats — Arc manufactures and sells high-performance electric boats for watersports.
Possible Ventures backs ambitious teams building frontier technology to positively impact society. We invest globally in the early stages, actively supporting founders via our collective of global entrepreneurs.
Show more...Investment focus
- Industry: Software, Information Technology, Biotechnology
- Stage:Seed, Pre-Seed, Series A
- Geography: Germany, Australia, United States
Investor stats
- Total investments: 117
- Round size: Seed $2M–$7M; Pre-Seed $350k–$2.5M; Series A $6.9M–$43M
- Lead/follow: 3% lead, 97% follow
Portfolio highlights
- Automata — Automata is a deep-tech company that creates products that empower people to automate physical work. The company's product, Eva, is a lightweight and affordable robot arm built for professionals in a production line, in a lab, a home workshop or even in a classroom. People don't need to be technical experts to communicate with robots. Theweb-based software platform can be programmed by anyone, anywhere, any time, from any device, making it easy to reconfigure for a wide range of different tasks.Automata was founded on 2015 and is headquartered in London, England.
- Eden Brew — Eden Brew is a ground-breaking new way to enjoy dairy products sustainably and nutritiously.
- Pow.bio — Pow.bio provides fermentation services for synthetic biology.
Rabobank emerged from several small agricultural cooperative banks, founded by Dutch farmers in the late nineteenth century. Food & Agriculture (F&A) is in our DNA, from which we built a unique position in the F&A sector as a key financier and international player, attributes which we leverage for the benefit of our stakeholders andportfolio companies. We recognise and understand the food security challenges lying ahead of us and how Innovation in F&A supply chains is key to the solution, which is why we are dedicated to committing capital to the space.
Show more...Investment focus
- Industry: Agriculture, AgTech, Farming
- Stage:Series A, Series B, Seed
- Geography: United States, The Netherlands, Canada
Investor stats
- Total investments: 20
- Round size: Series A $3.8M–$15M; Series B $7M–$10M
- Lead/follow: 5% lead, 95% follow
Portfolio highlights
- 30MHz — The data platform for horticulture | Sense. Act. Impact.
- BeeHero — BeeHero - Your precision pollination provider for almonds, berries, apples and more We raise and keep exceptional bees by combining generations of commercial beekeeping experience with cutting-edge technology. Get premium bees & pollinate your crops with precision.
- EarthOptics — EarthOptics is building the cloud-based machine learning platform for soil and ground management.
Formed in late 2006, the Brisbane Angels Pty Ltd is a large group of private investors who actively invest in early stage technology companies, usually in South East Queensland, Australia. The members are typically active or semi-retired former senior business executives, who apart from financial input can provide much needed value adding toinvestee companies through hands-on management experience and high level business networks.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Angel
- Geography: Australia, United States, New Zealand
Investor stats
- Total investments: 28
- Round size: Seed $347k–$835k; Angel $321k–$601k
- Lead/follow: 17% lead, 83% follow
Portfolio highlights
- Tribu — Here at tribu we aim to make running an MSP stress-free and simple. Remove complexity and repetitive shackles to give you the freedom in business so that you can have freedom in life.
- Avasa — Avasa is a medical device company. It helps to improve surgical procedures by developing novel implantable devices.
- One Key Access — One Key Access is an interface to the world of couriers to enable 24/7 frictionless deliveries.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Growth Capital for Leading Midwest Tech Companies
Show more...Investment focus
- Industry: Software, Information Technology, Enterprise Software
- Stage:Series A, Series B
- Geography: United States, Canada, Australia
Investor stats
- Total investments: 55
- Round size: Series A $500k–$7.8M; Series B $750k–$7M
- Lead/follow: 60% lead, 40% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- CloseSimple — CloseSimple is a real estate based software firm making conversation around buying or selling a house easier through Text Message & Email.
- Deck Commerce — Deck Commerce Order Management System (OMS) simplifies complex order processes to empower retailers to curate the best customer experience.
- Forj — Host your association's conferences, trade shows, or events on our highly customizable and interactive virtual event platform, backed by our customer success team.
ATP Innovations accelerates the growth of technology companies that target global markets, by providing advice and guidance from seasoned entrepreneurs, access to investors, customers and domain specialists, and world-class infrastructure tailored to the needs of startup companies. The ATP Innovations Accelerator HUB is home to Startmate, IgnitionLabs and university accelerator programs. ATP Innovations’ portfolio comprises over 65 companies from the software, hardware and life science sectors.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Pharmaceutical
- Geography: Australia
Investor stats
- Total investments: 1
- Lead/follow: no public data
Portfolio highlights
- Clarity Pharmaceuticals — Clarity is a clinical stage company developing products to address the growing need for the use of radiopharmaceuticals in oncology.
Movac is New Zealand's most experienced technology investor and is deeply integrated into the Kiwi tech sector. We've been actively investing since 1998.
Show more...Investment focus
- Industry: Software, E-Commerce, SaaS
- Stage:Seed, Series A
- Geography: New Zealand, United States, Australia
Investor stats
- Total investments: 30
- Round size: Seed $1.4M–$4.3M; Series A $774k–$16M
- Lead/follow: 43% lead, 57% follow
- Last fund: May invest from a new fund soon — last raise in 2016
Portfolio highlights
- Atomic — Atomic embeds native, actionable customer interaction inside your iOS, Android or web app. Turn your customer data and insights into loyalty, retention and conversion.
- ZeroJet — ZeroJet is the first jet propulsion system to be designed specifically for an electric motor, delivering the perfect balance of performance and runtime.
- Mint Innovation — Founded in 2016, members of the Mint Innovation team have a strong background in chemistry, biotechnology, and leveraging IP in the industrial sector. They are scaling their technology in their Auckland plant and labs to demonstrate the commercial application of their biometallurgy processes for metal recovery.
Understorey Ventures invests in critical solutions needed to restore planetary health.
Show more...Investment focus
- Industry: Software, Data and Analytics, Information Technology
- Stage:Series A
- Geography: United States
Investor stats
- Total investments: 2
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- FLINTpro — FLINTpro develops natural capital and carbon reporting software that supports organizations throughout their sustainability journey. It simplifies the processing of large and complex data sets, applies the latest scientific and analytical models and runs advanced simulations.
- HydGene Renewables — Our mission is to accelerate adoption of low carbon technology by providing an alternative green hydrogen solution.
NOAB Ventures operates as a venture capital firm.
Show more...Investment focus
- Industry: Solar, Energy, Energy Storage
- Stage:Pre-Seed
- Geography: Australia, New Zealand
Investor stats
- Total investments: 4
- Lead/follow: no public data
Portfolio highlights
- Relectrify — Unlocking extra lifetime and performance of batteries via advanced battery management (BMS) technology.
- Vertus Energy — We innovate to make fossil natural gas extinct.
- HydGene Renewables — Our mission is to accelerate adoption of low carbon technology by providing an alternative green hydrogen solution.
powerHouse is a New Zealand intellectual property commercialisation company investing to develop new spin-out ventures
Show more...Investment focus
- Industry: Solar, FinTech, Big Data
- Stage:Seed, Series A
- Geography: United States, New Zealand, The Netherlands
Investor stats
- Total investments: 8
- Round size: Series A $500k–$7M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- Granular — Granular Energy provides solutions for managing and trading clean energy. Our tools have been developed to support the recent emergence of 24/7 time-stamped energy certificates as well as traditional "annual" certificates.
- Granular Energy — Granular Energy provides solutions for managing and trading clean energy. Our tools have been developed to support the recent emergence of 24/7 time-stamped energy certificates as well as traditional "annual" certificates.
- Salient Predictions — Salient Predictions uses ML & ocean data to provide long range weather forecast for use in diverse industries.
Outset Ventures provides investment, facilities, and support for technology on the forefront of new industries to thrive.
Show more...Investment focus
- Industry: CleanTech, Biotechnology, Product Research
- Stage:Seed, Pre-Seed
- Geography: New Zealand
Investor stats
- Total investments: 3
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Daisy Lab — Daisy Lab pioneers precision fermentation technology in New Zealand
- Vertus Energy — We innovate to make fossil natural gas extinct.
- Aspiring Materials — Aspiring Materials. Civil Engineering and Geoengineering Research for the Future and Mars
Lilly Ventures is the venture capital arm of Eli Lilly and Company responsible for life science investing in North America and Europe. Its primary goal is to facilitate the success of companies in its areas of focus through early to expansion stage investments and value-adding resources. Lilly Ventures currently has $200 million under managementand focuses on three major areas of interest. It partner actively with the management teams of its portfolio companies to realize the potential of their technologies.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series C, Series B, Series A
- Geography: United States, Israel, Australia
Investor stats
- Total investments: 70
- Round size: Series A $8.9M–$28M; Series B $15M–$35M; Series C $4M–$44M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — last raise in 2009
Portfolio highlights
- IpiNovyx Bio — Orange Grove Bio partners with leading research universities to advance preclinical biotech programs in the oncology space. The company leverages its venture capital and drug development expertise to help patients and build biotech ecosystems.
- Evox Therapeutics — Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics. Backed by leading Life Sciences Venture Capital groups and supported by a comprehensive intellectualproperty portfolio, Evox’s mission is to positively impact human health by creating novel exosome-based therapeutics for the treatment of various severe diseases with limited options for patients and their families.Evox has created substantial proprietary technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies. Evox is leading the development within this emerging therapeutic space.
- Kymera Therapeutics — Advancing targeted protein degradation to deliver next-generation medicines
Bioplatforms Australia is a non-profit entity that supports life science research in genomic, proteomics, metabolomics, and bioinformatics.
Show more...Investment focus
- Industry: AgTech, Farming, Agriculture
- Stage:Pre-Seed
- Geography: Australia
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Number 8 bio — Number 8 bio objective is to decarbonize agriculture while feeding the world's rising population. This can be accomplished by harnessing the power of trillions of carbon-hungry bacteria that feed on harmful greenhouse gases and turn them into profitable animal feeds.
Southern Cross Venture Partners was launched in 2006 by veteran venture capitalists who have managed and operated companies themselves. Southern Cross Venture Partners assist early stage technology companies that demonstrate the potential for exceptional growth and market leadership build significant businesses. The founding principle of SouthernCross is partnership -- they are passionately committed to doing everything they can to help their portfolio companies succeed. Their team has a strong record of utilizing their start-up and management experience, industry knowledge, network of business/customer relationships, and recruiting skills to assist in building significant shareholder value.Southern Cross is currently investing in companies that fit their investment criteria. They prefer to act as lead or co-lead in the early stages where they have experience that can help build value rapidly. They do not have a minimum investment amount, however, a typical initial investment will be $2 million to $5 million with an ability to invest more money in later rounds.
Show more...Investment focus
- Industry: Software, Manufacturing, Renewable Energy
- Stage:Series B, Series A
- Geography: United States, Australia, Singapore
Investor stats
- Total investments: 49
- Round size: Series A $2M–$5M; Series B $5M–$15M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — raised $128M in 2012
Portfolio highlights
- Sunman — Sunman Energy is a technology company founded by a group of industry veterans delivering the future of Solar. Through the research and development of composite materials, Sunman has successfully commercialized the world’s first glass-free, lightweight and flexible Panel – eArc. Replacing glass completely, eArc brings solar power to markets andapplication scenarios that were previously impossible.
- Wave Computing — The future of high-tech in online casino is a bright one. For example, RFID technology will help casinos track and identify stolen chips. In addition, these systems can also predict player behavior and betting patterns. The latter are especially useful if a player is caught while he is trying to switch out his cards. These ... Read more
- Brisbane Materials Technology — Since 2005, we have helped thousands of people get the perfect domain name.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Grand Challenges Canada is dedicated to supporting Bold Ideas with Big Impact® in global health. They are funded by the Government of Canada and they fund innovators in low- and middle-income countries (LMICs) and Canada. The bold ideas they support integrate science and technology, social and business innovation – they call this IntegratedInnovation®. They focus on bringing successful innovation to scale, catalyzing sustainability and impact. They have a determined focus on results, and on saving and improving lives.Grand Challenges Canada works closely with Canada’s International Development Research Centre (IDRC), the Canadian Institutes of Health Research (CIHR) and Global Affairs Canada to catalyze scale, sustainability and impact. Grand Challenges Canada takes an evidence-based approach to development innovation to save and improve lives in LMICs. They are a platform for development innovation in Maternal, Newborn and Child Health (MNCH) through their Saving Lives at Birth, Saving Brains and MNCH Stars in Global Health programs. They are also focused on helping the poorest and most vulnerable populations, for example those who suffer from mental illness.Since their launch in 2010, Grand Challenges Canada has supported a pipeline of over 700 projects in more than 80 countries. Their investments are producing results: Thousands of lives have been saved and over two hundred and eighty thousand lives have been improved, thus far. By 2030, these innovations have the potential to save hundreds of thousands of lives and improve millions of lives.
Show more...Investment focus
- Industry: Health Care, Medical Device, Biotechnology
- Stage:Grant, Seed, Debt Financing
- Geography: Canada, United States, Australia
Investor stats
- Total investments: 11
- Round size: Grant $100k–$3.3M; Debt Financing $726k–$2M
- Lead/follow: 55% lead, 45% follow
Portfolio highlights
- OmniVis — OmniVis is a technology company creating handheld devices to rapidly detect dangerous pathogens - saving food and saving lives.
- Nivi, Inc. — Nivi is the best digital health chatbot built for whatsapp and rooted in behavioral science. Nivi enables users to take charge of their own health and works with private and public agencies to driver better public health outcomes.
- Sensoreal — Sensoreal Inc. is a diagnostic device and service provider company. The company is developing a variety of biosensors, which can perform one-step immunoassays in low-cost, accurate and quantifiable manners. Sensoreal was founded in 2014, and is headquartered in Montreal, Canada.
Custos Privatstiftung is a private company.
Show more...Investment focus
- Industry: Software, Biopharma, Nutrition
- Stage:Series B, Seed, Series C
- Geography: Israel, Austria, New Zealand
Investor stats
- Total investments: 4
- Lead/follow: no public data
Portfolio highlights
- Innovopro — Bringing a unique chickpea protein platform to the global food & beverage market, for creating nutritious, tasty, and sustainable food products.
- Helico — Helico is developing a proprietary computational platform for synthetic biology research using modelling tools and AI-based prediction algorithms. The long-term aim is to develop a seed bank of different drugs able to be licensed to grow medical supplies in confined greenhouses anywhere in the world.
- Authentic Vision — Protect your brand with anti counterfeiting technology from Authentic Vision, a leading provider of mobile authentication app solutions.
Thistledown Capital is a venture capital firm.
Show more...Investment focus
- Industry: Energy, Laser, Electronics
- Stage:Series A
- Geography: Canada, Germany, Australia
Investor stats
- Total investments: 3
- Lead/follow: no public data
Portfolio highlights
- Loam Bio — Loam Bio is developing tech that allows for crops to be inoculated with symbiotic micro-organisms.
- Marvel Fusion — Our mission is to enable humankind to access clean, safe & reliable energy by building a laser-driven fusion power plant.
- General Fusion — General Fusion is developing fusion energy: a clean, safe, abundant and on-demand approach to generating electricity.
Empath Ventures is a venture capital firm that mainly invests in psychedelic medicine companies. The firm specializes in the fields of investment financial services, finance, and venture capital. It was founded in 2021 and headquartered in Los Angeles California.
Show more...Investment focus
- Industry: Biotechnology
- Stage:Seed, Convertible Note
- Geography: Australia
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Psylo — Psylo is an Australia-based psychedelic biotech business focusing on Psychedelic-inspired medicine to treat mental illness.
- Kanna Health — Kanna Health is a preclinical stage biopharma company developing novel therapeutics from kanna alkaloids to alleviate patient suffering and unmet medical needs.
Even Capital operates as an investment firm.
Show more...Investment focus
- Industry: FinTech, Biotechnology, Product Research
- Stage:Seed, Series C
- Geography: New Zealand
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- Daisy Lab — Daisy Lab pioneers precision fermentation technology in New Zealand
- Sharesies — Sharesies allows you to get started investing from just $5.
Twynam Group is a leading Australian Funds Manager investing in early-stage climate tech. We also operate an agricultural and property portfolio.
Show more...Investment focus
- Industry: Agriculture, Food Processing, Seafood
- Stage:Series A, Seed
- Geography: United States, Australia, Singapore
Investor stats
- Total investments: 11
- Round size: Seed $1.9M–$3.6M; Series A $3.4M–$33M
- Lead/follow: 17% lead, 83% follow
Portfolio highlights
- Earthodic — Earthodic is an Australian materials science company creating functional biobased coatings. Paperbarc by Earthodic is a biobased water-resistant coating for pulped or paper products. It has better water-resistance than wax coatings, more sustainable and circular than plastic coatings. Repulpable. Re
- BetaCarbon — BetaCarbon is the first and only digital token notionally linked to Australian Carbon Credit Units (ACCU.) ACCUs are a regulated financial asset issued by the Clean Energy Regulator, an Australian government-linked entity.
- Ocean Rainforest — Ocean Rainforest offer a collection of premium fully-traceable seaweed products, mostly for food and cosmetic producers.
UniSA Ventures is the technology commercialisation and investment management company of the University of South Australia (UniSA).
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed
- Geography: Australia
Investor stats
- Total investments: 2
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
- Framework — All-in-one productivity tool for teams & individuals.
Investible is an early-stage venture capital firm backing the visionaries advancing humanity through technology in Australia, New Zealand, Southeast Asia and globally.
Show more...Investment focus
- Industry: Software, E-Commerce, Information Technology
- Stage:Seed, Series A, Pre-Seed
- Geography: Australia, United States, Singapore
Investor stats
- Total investments: 104
- Round size: Seed $125k–$2.1M; Pre-Seed $642k–$1M; Series A $1M–$6.1M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Earthodic — Earthodic is an Australian materials science company creating functional biobased coatings. Paperbarc by Earthodic is a biobased water-resistant coating for pulped or paper products. It has better water-resistance than wax coatings, more sustainable and circular than plastic coatings. Repulpable. Re
- Restoplus — Checkout our point of sale, website, online ordering, qr code table ordering, and table booking. Contact our experts to learn more.
- Betterdata — Better Data Our technology makes data sharing instant and secure by converting limited real data into limitless synthetic data that looks, feels behaves just like real data
Playford Capital is a venture capital arm of South Australian Government Financing Authority specializing in investments in start-ups, early venture, mid venture, late venture stages, and growth capital.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Series B
- Geography: Australia
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Signostics — Signostics produces Biotech medical devices. Their flagship product, Signos, allows healthcare professionals to use ultrasound in their clinical practice. It offers ultrasound platform technology that clinicians can place in their pocket or wear around their neck like a stethoscope. Just as handheld devices transformed the business world, it isanticipated the Signos will change the way healthcare professionals practice medicine.Signostics was established in Adelaide, Australia in 2005 and expanded into the U.S. in 2008, dedicated to developing fast and affordable pointâ€ofâ€care medical devices. The company launched its first product into the veterinarian market in January 2009 andgained regulatory approvals to enter the human medical device market for the United States, Europe, and Australia in May 2009. Signostics has offices in Palo Alto, California and Adelaide, South Australia.
HealthCare Ventures is a leading life science venture capital firm investing in pre-clinical or early clinical stage, focused companies with potential to transform patient care.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series B, Series A, Series C
- Geography: United States, Australia, United Kingdom
Investor stats
- Total investments: 102
- Round size: Series A $4.4M–$37M; Series B $10M–$50M; Series C $10M–$44M
- Lead/follow: 18% lead, 82% follow
- Last fund: May invest from a new fund soon — last raise in 2010
Portfolio highlights
- Colorescience — Know Better Skin with Colorescience. From mineral sunscreen to clinical skincare products, achieve a clear, even complexion and protect your skin from the damaging effects of the sun and environmental aggressors such as pollution. Shop Now!
- Leap Therapeutics — Leap Therapeutics, Inc., a clinical-stage biopharmaceutical company, is engaged in acquiring and developing novel therapeutics. The company focus is to identify translational-stage molecules in the areas of cell signaling and immuno-oncology.
- Proteostasis Therapeutics — Proteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body's protein homeostasis, or Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases. These novel therapies, or Proteostasis Regulators, aredesigned to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as emphysema, type II diabetes, Alzheimer's Disease and Huntington's Disease.
FAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotechnology VC Funds in Oceania investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 48,091 VC funds investing in Oceania Biotechnology startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!